The effect of vernakalant (RSD1235), an investigational antiarrhythmic agent, on atrial electrophysiology in humans.

Objectives:To determine the acute effects of vernakalant (RSD1235) on electrophysiologic (EP) properties in humans.Background:Vernakalant is an investigational mixed ion channel blocker that can terminate acute atrial fibrillation (AF) in humans at 2 to 5 mg/kg and may be more “atrial-selective” tha